<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01864850</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC ELAN-RT</org_study_id>
    <nct_id>NCT01864850</nct_id>
  </id_info>
  <brief_title>Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC</brief_title>
  <acronym>ELAN-RT</acronym>
  <official_title>Non Inferiority Randomized Trial of Standard Radiotherapy Versus Hypofractionated Split Course Radiotherapy in Elderly Vulnerable Patients With Inoperable Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Oncologie Radiotherapie Tete et Cou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized comparison between standard radiotherapy and hypofractionated split course
      schedule. Compared to standard radiotherapy, the investigators expect that hypofractionated
      split course (interruption of 2 weeks) radiotherapy will improve compliance to treatment,
      acute tolerance of treatment, preservation of autonomy, prevention of malnutrition, with the
      same efficacy, measured by the locoregional control rate.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 18, 2013</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Actual">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Locoregional control</measure>
    <time_frame>6 months</time_frame>
    <description>Patient alive with locoregional control at 6 months after the end of radiotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>3 months</time_frame>
    <description>Acute toxicity according to the CTC NCI V4 - rate of toxicity by type and by grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>18 months</time_frame>
    <description>Late toxicity according to the RTOG late toxicity scale - rate of toxicity by type and by grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomy</measure>
    <time_frame>18 months</time_frame>
    <description>Autonomy according to ADL scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>18 months</time_frame>
    <description>Quality of life according to EORTC QLQ-C30 and QLQ-HN35</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>18 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional progression</measure>
    <time_frame>18 months</time_frame>
    <description>Locoregional progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metastasis progression</measure>
    <time_frame>18 months</time_frame>
    <description>metastasis progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>18 months</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Standard RT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>70 Gy / 7 weeks / 2 Gy per fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypofractionated RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard RT</intervention_name>
    <description>70 Gy / 7 weeks / 2 Gy per fraction</description>
    <arm_group_label>Standard RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated RT</intervention_name>
    <description>55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy</description>
    <arm_group_label>Hypofractionated RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 70 or over

          -  SIOG group 2 (vulnerable)

          -  Life expectancy &gt; 12 weeks

          -  PS &lt; 2

          -  Histologically confirmed diagnosis of squamous cell carcinoma of head and neck: oral
             cavity, oropharynx, nasopharynx, hypopharynx, larynx, cervical nodes (unknown
             primary).

          -  First line treatment

          -  At least one measurable lesion (RECIST)

          -  Stage II to IV

          -  Patients unsuitable for surgery of the primary tumour: non resectable tumor,
             anesthesia contra indication, patient's refusal, or organ sparing approach. Cervical
             nodes dissection authorized

          -  Patients planned to be treated in a curative intent with radiotherapy alone on primary
             tumor site and on at least one head and neck node area

          -  Consent form signed

        Exclusion Criteria:

          -  Primary squamous cell carcinoma of sinus, the skin or of the salivary glands

          -  Stage I cancer

          -  Radiotherapy planned on primary tumor only, or on neck nodes only. For patients with
             metastatic lymph nodes from unknown primary head and neck squamous cell carcinoma,
             patients will be excluded if head and neck mucosa (oropharynx, larynx, hypopharynx) is
             not included as a target volume for radiotherapy

          -  Prior radiotherapy of head and neck area

          -  Concurrent chemotherapy or immunotherapy or hormonotherapy

          -  Induction chemotherapy

          -  Concomitant infection requiring IV antibiotics

          -  cancer other than head and neck cancer within the previous 5 years (baso cellular skin
             carcinoma and cervix carcinoma excepted)

          -  conditions that could lead to bad compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Princesse Grace</name>
      <address>
        <city>Monaco</city>
        <zip>98 000</zip>
        <country>Monaco</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Monaco</country>
  </location_countries>
  <link>
    <url>http://www.gortec.fr/</url>
    <description>GORTEC</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 21, 2013</study_first_submitted>
  <study_first_submitted_qc>May 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2013</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HNSCC</keyword>
  <keyword>Elderly</keyword>
  <keyword>Geriatry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data Monitoring Committee will meet every year either by a physical meeting or by conference call. Data on the recruitment, toxicity and autonomy are submitted every year.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

